loading page

Prolonged remission using CD19 chimeric antigen receptor-T cell therapy followed by haploidentical transplantation in a 5-month-old patient with infantile acute lymphoblastic leukemia
  • +2
  • Tamara Hagoel,
  • Bree Kramer,
  • Joanne Becker,
  • Kara Kelly,
  • Meghan Higman
Tamara Hagoel
Roswell Park Comprehensive Cancer Center
Author Profile
Bree Kramer
University at Buffalo Jacobs School of Medicine and Biomedical Sciences
Author Profile
Joanne Becker
Roswell Park Comprehensive Cancer Center
Author Profile
Kara Kelly
Roswell Park Comprehensive Cancer Center
Author Profile
Meghan Higman
Roswell Park Comprehensive Cancer Center
Author Profile

Abstract

Tisagenlecleucel offers promise to children with relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL). However, there is limited experience with and data supporting the use of tisagenlecleucel in infants. We describe our successful experience using tisagenlecleucel followed by a haploidentical donor hematopoietic stem cell transplantation in an infant with r/r KMT2A-rearranged ALL, the youngest infant to survive and achieve prolonged remission using this approach.